PeptideStack
5.2kquestions
20kanswers
220users

Is 99.1% a realistic purity ceiling for tirzepatide given its chain length?

Asked 9 Feb 2025Modified 15 months agoViewed 25k times
30

The case in front of me: 99.1% · tirzepatide.

I want the working, not the result — I need to be able to redo it with different numbers.

I care about the precision as well as the value — I want to know how many figures are real.

Is my approach right even if my number is wrong?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

788 questions
hplc
hplc

Reverse-phase high-performance liquid chromatography, the workhorse purity method. Column chemistry, mobile-phase choice, gradient slope,…

466 questions
peptide-mapping
peptide-mapping

Enzymatic digestion followed by LC-MS/MS to confirm sequence rather than just mass. The method that catches a scrambled sequence or a D-amino-acid…

83 questions
shareeditfollowflag
BN
askedbridget_nyathi16k179 Feb 2025
6This should probably be in the site help pages rather than buried in an answer. – Dr_Ravi_Selvarajah 9 months ago
5Good answer, but the confidence interval in the cited trial is wider than implied. – ivo_paunovic 7 months ago
add a comment

5 Answers

Sorted by votes
41

The single most important distinction is between what purity measures — the fraction of detected material that is your target — and what you actually want to know — how much of the material in the vial is your target.

Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.

Mass shifts and what they usually mean

Δ mass (Da)Most likely causeDistinguishing feature
+1Deamidation (Asn or Gln)New peak, slightly earlier retention
−17Loss of ammoniaOften with deamidation
−18Dehydration / succinimidepH-dependent, reversible
+16Oxidation (Met, Trp)Earlier retention, light-related
−128Missing Gln or LysDeletion sequence from synthesis
0Isomer: racemisation or scramblingSame mass, shifted retention

Worth being precise here: tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.

The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.

One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
TQ
answeredtriple_agonist_q37k386 Apr 2025
2This should probably be in the site help pages rather than buried in an answer. – sasha_ferreira 6 months ago
Good answer, but the confidence interval in the cited trial is wider than implied. – tobias_maartens 4 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
26

Purity is a method-dependent figure, and that is not a limitation of the measurement, it is a property of what the measurement actually answers.

The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

On the detail: retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.

Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

edited 1 May 2025 by sian_llewellyn — corrected a unit error in the worked example

shareimprove this answerflag
SL
answeredsian_llewellyn85k24817 Apr 2025
19

Identity and purity are orthogonal, and a high purity says almost nothing about whether the peak is actually what you think it is.

Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.

Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.

Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.

If you are ranking vendors, specify a method and have all samples tested at the same place.

shareimprove this answerflag
RP
answeredravi_pillai16k2815 Mar 2025
7This is the answer I was looking for three months ago. – pierce_count 10 months ago
6The arithmetic checks out. I ran the same numbers and got the same result. – ines_brandt 8 months ago
add a comment
16

Put another way, the honest answer is that the achievable range of plausible purity figures for a given vial is wider than most people expect.

Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.

Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
HP
answeredh_pergande86k25821 Feb 2025
15

On the detail: gradient slope is the most powerful parameter and almost nobody mentions it, which is why two reports on the same material disagree by a point.

Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.

Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
TA
answeredtess_amankwah48k3826 Mar 2025
3The placebo-arm figure is the part everyone omits. – siobhan_deasy 5 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.